GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Axsome Therapeutics Inc (NAS:AXSM) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)

Axsome Therapeutics (Axsome Therapeutics) EPS Growth Rate (Future 3Y To 5Y Estimate) : N/A (As of Apr. 30, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Axsome Therapeutics EPS Growth Rate (Future 3Y To 5Y Estimate)?

EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Axsome Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) is N/A.


Competitive Comparison of Axsome Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate)

For the Biotechnology subindustry, Axsome Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate), along with its competitors' market caps and EPS Growth Rate (Future 3Y To 5Y Estimate) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Axsome Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) distribution charts can be found below:

* The bar in red indicates where Axsome Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) falls into.



Axsome Therapeutics  (NAS:AXSM) EPS Growth Rate (Future 3Y To 5Y Estimate) Explanation

EPS Growth Rate (Future 3Y To 5Y Estimate) s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.


Axsome Therapeutics EPS Growth Rate (Future 3Y To 5Y Estimate) Related Terms

Thank you for viewing the detailed overview of Axsome Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) provided by GuruFocus.com. Please click on the following links to see related term pages.


Axsome Therapeutics (Axsome Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Axsome Therapeutics Inc (NAS:AXSM) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)
Traded in Other Exchanges
Address
22 Cortlandt Street, 16th Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14.
Executives
Susan Mahony director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Mark Coleman director 25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Hunter R. Murdock officer: General Counsel 22 CORTLAND STREET, 16TH FLOOR, NEW YORK NY 10007
Roger Jeffs director
Nick Pizzie officer: Chief Financial Officer 25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Mark E Saad director C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
Herriot Tabuteau director, 10 percent owner, officer: CHIEF EXECUTIVE OFFICER
Mark L. Jacobson officer: Chief Operating Officer 200 BROADWAY, 3RD FLOOR, NEW YORK NY 10038
David C Marek officer: Chief Commercial Officer C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
John Golubieski officer: Chief Financial Officer C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA NY 01862
Myrtle S Potter director 10 FINDERNE AVE, BRIDGEWATER NJ 08807
Randall Kaye officer: Chief Medical Officer 11388 SORRENTO VALLEY ROAD, STE. 200, SAN DIEGO CA 92121
Ames Constance officer: Vice President, Finance 25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Antecip Capital Llc 10 percent owner 630 5TH AVENUE, SUITE 2074, NEW YORK NY 10111